Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger
Recce Pharmaceuticals (ASX:RCE) has been on a tear this year. It's developing anti-infective, R327, with clinical results across Diabetic Foot Infection, Acute Bacterial Skin & Skin Structure Infection, and, Urosepsis/UTIs which point to a potential commercial value proposition. It also has a recent key relationship in Indonesia.
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Latest Threads
Tag | Subject | ||||||
---|---|---|---|---|---|---|---|
CCC | Ann: Board Change | 01/10/24 | 0 | 38 | |||
|
|||||||
CCC | Ann: AGM Voting Results | 10/09/24 | 0 | 44 | |||
|
|||||||
CCC | Ann: Cooks Coffee Company Trading Update | 10/09/24 | 0 | 62 | |||
|
|||||||
CCC | Ann: 2024 AGM Presentation | 10/09/24 | 0 | 49 | |||
|
|||||||
CCC | Ann: Director disclosure notice | 29/08/24 | 0 | 54 | |||
|
|||||||
CCC | Ann: Annual Meeting Notice of Meeting - 10th September 2024 | 23/08/24 | 0 | 82 | |||
|
|||||||
CCC | Ann: Cooks Capital Change Notice | 12/08/24 | 0 | 71 | |||
|
|||||||
CCC | Ann: Keith Jackson & others - SPH notice | 12/08/24 | 0 | 54 | |||
|
See All Discussions